$PKTX rotoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC Marietta, Ohio, July 9, 2019 ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) has reached the mid-point of 3rdstage of testing in retinal cell replacement therapy at the University of British Columbia. Functionality testing on experimental models three months post-transplant show encouraging results. We anticipate results from six-month post-transplant to be available within the next 4-5 weeks. The study includes two experimental models over a longer period of time to test whether the AAGP® treated cells continue to develop and mature into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
“We are pleased that our functional studies to date are looking positive and very significant.” – Dr. Kevin Gregory-Evans
Dr. Kevin Gregory-Evans on ProtoKinetix AAGP® Dr. Gregory-Evans Bio
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.